INOVIO estimates cash and investments at about $48.4M

The company says actual quarter-end results may differ materially from the preliminary estimate as it completes its closing procedures.

Available on EDGAR 11/05/2026 - 04:13 PM EST Accepted by SEC EDGAR 11/05/2026 - 04:13 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

INOVIO PHARMACEUTICALS, INC. estimated that its cash, cash equivalents and short-term investments were approximately $48.4 million as of September 30, 2026. The preliminary, unaudited estimate is based on management estimates, is not a comprehensive statement of quarterly financial results, and remains subject to completion of closing procedures. Ernst & Young LLP did not audit or review the preliminary data and expressed no opinion or other assurance.

8-K Event Classification

Item 2.02 — Results of Operations and Financial Condition

1 item

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Key Figures

Cash, cash equivalents and short-term investments: Approximately $48.4 million

1 metrics

Cash, cash equivalents and short-term investments Approximately $48.4 million Preliminary estimate as of September 30, 2026

Key Terms

cash equivalents, short-term investments, forward-looking statements

3 terms

cash equivalents financial

"cash, cash equivalents and short-term investments"

Cash equivalents are short-term, highly safe investments that a company can quickly turn into cash, such as Treasury bills, money-market accounts or very short-term bank deposits. Think of them like a spare set of ready cash in a high-quality savings jar that can be tapped immediately. Investors watch this balance because it shows how easily a company can cover bills, weather shocks, or seize sudden opportunities without selling long-term assets.

short-term investments financial

"cash, cash equivalents and short-term investments"

Short-term investments are financial assets purchased with the goal of turning them back into cash within about a year, including things like Treasury bills, money market funds, and short-duration bonds. They matter to investors because they provide a lower-risk, more accessible place to park money than stocks or long-term bonds—like a nearby savings box that earns some interest while staying ready for immediate needs or opportunities.

forward-looking statements regulatory

"contains forward-looking statements"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was INO's estimated cash balance as of September 2026?

INOVIO estimated cash, cash equivalents and short-term investments at approximately $48.4 million as of September 30, 2026; the preliminary, unaudited estimate remains subject to completion of closing procedures.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false 0001055726 0001055726 2026-11-05 2026-11-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 5, 2026

Inovio Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-14888		33-0969592
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

660 W. Germantown Pike Suite 110

Plymouth Meeting, PA 19462

(Address of principal executive offices, including zip code)

(267) 440-4200

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		INO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

Inovio Pharmaceuticals, Inc. (the “Company”) is providing the following financial information. As of September 30, 2026, the Company estimates that its cash, cash equivalents and short-term investments were approximately $48.4 million.

The cash, cash equivalents and short-term investments information above is based on preliminary unaudited information and management estimates for the quarter ended September 30, 2026, is not a comprehensive statement of the Company’s financial results as of and for the quarter ended September 30, 2026, and is subject to completion of the Company’s financial closing procedures.

The preliminary financial data included in this current report has been prepared by, and is the responsibility of, the Company’s management. Ernst & Young LLP has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, Ernst & Young LLP does not express an opinion or any other form of assurance with respect thereto.

The information in this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report on Form 8-K shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements regarding the preliminary estimate of the Company’s cash, cash equivalents and short-term investments as of September 30, 2026. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements, including, without limitation, the Company’s actual results for the quarter ended September 30, 2026 may differ materially from the Company’s preliminary estimates as a result of changes to assumptions and estimates, the completion of review of internal controls over financial reporting or other quarter-end and year-end procedures. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding the Company’s business are described in detail in its SEC filings, including, in the section of the prospectus supplement titled “Risk Factors,” filed with the SEC on November 5, 2026, the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, which are available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that the Company makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and the Company disclaims any obligation to update these statements except as may be required by law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				INOVIO PHARMACEUTICALS, INC.
Date: November 5, 2026				By:		/s/ Peter Kies
						Peter Kies
						Chief Financial Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB